Dear Type 1 Diabetes Community,

The Iacocca Family Foundation is assessing its future philosophy and process in reviewing all philanthropic proposals.  Consequently, we will not be accepting any new proposals until further notice.  All updates will be posted on our website.

Thank you for your continued efforts in the search for a cure for Type 1 Diabetes; we are pleased to be part of this important quest.

Sincerely,
Kathryn Iacocca Hentz


The Foundation has funded over $45 million in innovative and promising Type 1 Diabetes research programs and projects that will lead to a cure for the disease and alleviate complications caused by it.

Type 1 diabetes, or insulin-dependent disease, is an autoimmune disorder in which the body does not produce insulin, the hormone necessary for the body to metabolize sugar. Without insulin, sugar cannot move from blood into the cells, causing the blood sugar to rise above a safe level and leaving cells without the ability to function properly. Type 1 is also known as Juvenile Diabetes. It is a lifelong disease and has many complications.

Grant Recipients

Teresa P. DiLorenzo, Ph.D. Teresa P. DiLorenzo, Ph.D.
The DiLorenzo laboratory seeks to suppress only those T cells involved in type 1 diabetes that are responsible for destroying the beta cells. These T cells bind beta cell peptides that activate the T cells and cause them to destroy the beta cells. Read More

Grant Recipients

Denise FaustmanDenise Faustman, M.D., Ph. D.
Dr. Faustman is leading the human clinical trial program at Massachusetts General Hospital testing Bacillus Calmette-Guérin (BCG), an inexpensive generic drug, as a treatment for advanced type 1 diabetes.Read More

Grant Recipients

Maike Sander, M.D. Maike Sander, M.D.
Dr. Sander’s laboratory seeks to investigate a novel signaling pathway that her laboratory found to stimulate beta cell proliferation. Read More

Grant Recipients

Ivana Stojanovic, Ph.D. Ivana Stojanovic, Ph.D.
Dr. Stojanovic’s laboratory focuses on utilizing insulin-specific effector T cells that promote beta cell destruction and converting them in vitro into insulin-specific T regulatory cells using different manipulations. Read More

Grant Recipients

Roland Tisch, Ph.D. Roland Tisch, Ph.D.
The Tisch group is focused on obtaining proof-of-principle that ND antibodies specific for human CD4 and CD8, recently established by the group, selectively suppress tissue destructive human T cells. Read More

1 2 3 4 5

Join Our Mailing List!